Immix Biopharma says NEXICART-2 interim data show 89% complete response rate for NXC-201
IMMX•Immix Biopharma said interim NEXICART-2 results showed an 89% complete response rate for NXC-201 in relapsed or refractory AL amyloidosis. The company plans a final readout and BLA submission for mid-2027.
1. Interim trial results
Immix Biopharma reported interim NEXICART-2 results for NXC-201 in relapsed or refractory AL amyloidosis, showing an 89% complete response rate. The company said several additional patients were already disease-negative in bone marrow and could convert to complete remission over time.
2. Response and safety
No relapses have been seen so far among patients who achieved deep responses. Immix said no neurotoxicity or enterocolitis had been observed to date.
3. Planned next steps
The company plans a final NEXICART-2 readout and a BLA submission for mid-2027.
